Insider Buying: GSK (LON:GSK) Insider Acquires £31,754.45 in Stock

GSK plc (LON:GSK) insider Anne Beal acquired 637 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average price of GBX 4,985 per share, for a total transaction of £31,754.45.

GSK Price Performance

Shares of LON GSK opened at GBX 1,877 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The stock has a fifty day simple moving average of GBX 1,888.78 and a two-hundred day simple moving average of GBX 1,949.39. GSK plc has a 1-year low of GBX 1,455 and a 1-year high of GBX 2,282. The firm has a market cap of £75.21 billion, a price-to-earnings ratio of 15.93, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last issued its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analyst Weigh In

GSK has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 2,000 price objective on shares of GSK in a report on Tuesday, September 15th. Berenberg Bank lifted their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a research note on Tuesday, September 8th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of GBX 2,064.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.